Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Joanna Vergidis"'
Autor:
Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts, Wilson Tu, William Fan, Andrew J. Murtha, Catarina Kollmannsberger, Edmond M. Kwan, Karan Parekh, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Sarah W. S. Ng, Takayuki Sumiyoshi, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Stacy Miller, Sunil Parimi, Jean-Michel Lavoie, Edward Hardy, Maryam Soleimani, Lucia Nappi, Bernhard J. Eigl, Christian Kollmannsberger, Sinja Taavitsainen, Matti Nykter, Sofie H. Tolmeijer, Emmy Boerrigter, Niven Mehra, Nielka P. van Erp, Bram De Laere, Johan Lindberg, Henrik Grönberg, Daniel J. Khalaf, Matti Annala, Kim N. Chi, Alexander W. Wyatt
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratific
Externí odkaz:
https://doaj.org/article/6914ec1e3ba942ee99b1463117270db9
Autor:
Kim N. Chi, Alexander W. Wyatt, Martin E. Gleave, Matti Nykter, Arun A. Azad, Muhammad Zulfiqar, Joanna Vergidis, Conrad D. Oja, Daygen Finch, Bernhard J. Eigl, Christian Kollmannsberger, Katherine Sunderland, Evan W. Warner, Kevin Beja, Sinja Taavitsainen, Daniel Khalaf, Gillian Vandekerkhove, Matti Annala
Supplementary Tables S1 - S9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3817d8a283a1763bf881666a0afc30a0
https://doi.org/10.1158/2159-8290.22533116
https://doi.org/10.1158/2159-8290.22533116
Autor:
Kim N. Chi, Alexander W. Wyatt, Martin E. Gleave, Matti Nykter, Arun A. Azad, Muhammad Zulfiqar, Joanna Vergidis, Conrad D. Oja, Daygen Finch, Bernhard J. Eigl, Christian Kollmannsberger, Katherine Sunderland, Evan W. Warner, Kevin Beja, Sinja Taavitsainen, Daniel Khalaf, Gillian Vandekerkhove, Matti Annala
Supplementary Figures S1 - S18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca8a7ed19096ba47511c436b9b11f8e
https://doi.org/10.1158/2159-8290.22533119.v1
https://doi.org/10.1158/2159-8290.22533119.v1
Autor:
Alexander W. Wyatt, Kim N. Chi, Martin E. Gleave, Matti Nykter, Christian K. Kollmansberger, Bernhard J. Eigl, Muhammad Zulfiqar, Joanna Vergidis, Conrad D. Oja, Daygen L. Finch, Simon Fu, Amanda Wong, Cameron Herberts, Evan W. Warner, Joonatan Sipola, Kevin Beja, Gillian Vandekerkhove, Daniel J. Khalaf, Sinja Taavitsainen, Matti Annala
Supplementary Figure S5 provides an overview of per patient ctDNA fraction and sequential treatment response (best prostate-specific antigen (PSA) decline and duration of response).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9cd9214aabbc30ab4f2c361cfa7ead
https://doi.org/10.1158/1078-0432.22481786.v1
https://doi.org/10.1158/1078-0432.22481786.v1
Autor:
Alexander W. Wyatt, Kim N. Chi, Martin E. Gleave, Matti Nykter, Christian K. Kollmansberger, Bernhard J. Eigl, Muhammad Zulfiqar, Joanna Vergidis, Conrad D. Oja, Daygen L. Finch, Simon Fu, Amanda Wong, Cameron Herberts, Evan W. Warner, Joonatan Sipola, Kevin Beja, Gillian Vandekerkhove, Daniel J. Khalaf, Sinja Taavitsainen, Matti Annala
Purpose:Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance.Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4482389c74ec8a30d9fcab11adbfefa4
https://doi.org/10.1158/1078-0432.c.6530771.v1
https://doi.org/10.1158/1078-0432.c.6530771.v1
Autor:
Alexander W. Wyatt, Kim N. Chi, Martin E. Gleave, Matti Nykter, Christian K. Kollmansberger, Bernhard J. Eigl, Muhammad Zulfiqar, Joanna Vergidis, Conrad D. Oja, Daygen L. Finch, Simon Fu, Amanda Wong, Cameron Herberts, Evan W. Warner, Joonatan Sipola, Kevin Beja, Gillian Vandekerkhove, Daniel J. Khalaf, Sinja Taavitsainen, Matti Annala
An excel file containing Supplementary Tables S1 - S10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44c5e528e2667eb9b961ca71cc94669a
https://doi.org/10.1158/1078-0432.22481768
https://doi.org/10.1158/1078-0432.22481768
Autor:
Daniel Khalaf, Maryam Soleimani, Werner Struss, Daygen Finch, Katherine Sunderland, Joanna Vergidis, Kevin Zou, Christian Kollmannsberger, Krista Noonan, B.J. Eigl, Muhammad Zulfiqar, Kim N. Chi, Lucia Nappi
Publikováno v:
European Journal of Cancer. 152:215-222
Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population.To compare the clinical e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c18544fad0199a9210d0c9f5ba94ee
https://doi.org/10.1016/j.ejca.2021.05.003
https://doi.org/10.1016/j.ejca.2021.05.003
Autor:
Conrad D. Oja, Amanda Wong, Simon Yuen Fai Fu, Bernhard J. Eigl, Sinja Taavitsainen, Joonatan Sipola, Muhammad Zulfiqar, Gillian Vandekerkhove, Evan W. Warner, Kevin Beja, Matti Nykter, Kim N. Chi, Matti Annala, Martin E. Gleave, Christian K. Kollmansberger, Cameron Herberts, Daniel Khalaf, Daygen Finch, Joanna Vergidis, Alexander W. Wyatt
Publikováno v:
Clinical Cancer Research. 27:4610-4623
Purpose:Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance.Ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9c0810a00f22d5206067d676f19534
https://doi.org/10.1158/1078-0432.ccr-21-1625
https://doi.org/10.1158/1078-0432.ccr-21-1625
Autor:
Alexander W. Wyatt, Krista Noonan, Daygen Finch, Joanna Vergidis, Christian Kollmannsberger, Conrad D. Oja, Andrew Attwell, Katherine Sunderland, Susan Ellard, Bernhard J. Eigl, Bruce Keith, Muhammad Zulfiqar, Arun Azad, Sinja Taavitsainen, Lyly H. Le, Deepa Wadhwa, Kim N. Chi, Daniel Khalaf, Matti Annala, Martin E. Gleave
Publikováno v:
The Lancet Oncology. 20:1730-1739
Summary Background Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both drugs, as well as their second-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e74c4730640ed8a565e7fa8e1eff7c2
https://doi.org/10.1016/s1470-2045(19)30688-6
https://doi.org/10.1016/s1470-2045(19)30688-6
Autor:
Corinne Maurice-Dror, Nicolette Fonseca, Cameron Herberts, Edmond Michael Kwan, Catarina Kollmannsberger, Wilson Tu, Daniel Joseph Khalaf, Matti Annala, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Joanna Vergidis, Krista Noonan, Daygen L. Finch, Muhammad Zulfiqar, Miller Stacy, Alexander William Wyatt, Kim N. Chi
Publikováno v:
Journal of Clinical Oncology. 40:5055-5055
5055 Background: Deleterious alterations in tumor suppressor genes (TSGs) TP53, RB1, and PTEN are potential markers of small cell neuroendocrine prostate cancer (SCNP), and androgen receptor pathway inhibitor (ARPI) resistance. We examined the outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff68250a103e47ebc061da4411dbcbb5
https://doi.org/10.1200/jco.2022.40.16_suppl.5055
https://doi.org/10.1200/jco.2022.40.16_suppl.5055